News Business and Finance

Bharat Biotech commences direct supply of ‘Covaxin’ to 14 states

0 blank 0
Read Time:59 Second

Bharat Biotech has commenced direct supply of its COVID-19 vaccine ‘Covaxin’ to 14 states, including Delhi and Maharashtra, with effect from May 1, according to the company’s Joint Managing Director Suchitra Ella.

The Hyderabad-based firm has started supplying its COVID-19 treatment vaccine to the states based on the allocations received by the central government.

“Bharat Biotech confirms direct supplies of COVAXIN to the following state govt’s since 1/5/21, based on the allocations received by GoI. Requests have been received from other states, & will be processed for distribution based on availability of stocks 24×7,” Ella tweeted.

The company is supplying vaccines to Andhra Pradesh, Assam, Chhattisgarh, Gujarat, Jammu & Kashmir, Jharkhand, Madhya Pradesh, Odisha, Tamil Nadu, Telangana, Uttar Pradesh and West Bengal.

On April 29, Bharat Biotech announced a cut in the price of ‘Covaxin’ for states to Rs 400 per dose from the earlier Rs 600 per dose.

This followed widespread criticism of its pricing policy as it sold Covaxin to the central government at Rs 150 per dose.

India has announced expansion of its COVID-19 vaccination drive by allowing its large 18-plus population to get inoculated from May 1.

blank

About Post Author

The Business Daily

The Business Daily is North East India’s first Financial News Portal. This Pink Portal covers all big breaking news from the world of Business, Brands, Politics, Entertainments, Sports etc.
Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
blank
The Business Daily
The Business Daily is North East India’s first Financial News Portal. This Pink Portal covers all big breaking news from the world of Business, Brands, Politics, Entertainments, Sports etc.
http://www.thebusinessdaily.in

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published.